WuXi PharmaTech Added to Prestigious Deloitte Technology Fast 500 Asia Pacific
Nov 19, 2004
November 19, 2004 - Shanghai, China - Deloitte named WuXiPharmaTech, China's leading chemistry-based pharmaceutical research and development service company, to the prestigious Deloitte Technology Fast 500 Asia Pacific 2004 in recognition of its rapid revenue growth over the past three years. The Deloitte Technology Fast 500 Asia Pacific program singles out fast-growing technology companies across Asia Pacific for the inclusion in the distinguished list. The coveted slots are sought by competitors from Australia, China/Hong Kong, India, Japan, Korea, Malaysia, New Zealand, Singapore, Taiwan, Thailand and other Asian regions and countries.
Dr Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, said: "We're honored by this selection. We want to share this honor with our collaboration partners to thank them for their continuous support of WuXi PharmaTech. We are now even more obligated to continue to improve our services to serve our partners better and better."
About WuXi PharmaTech (Cayman) Inc.
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: www.wuxiapptec.com.